AG
TVRD

Advisor Group’s Tvardi Therapeutics TVRD Stock Holding History

Advisor Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$94K Sell
161
-112
-41% -$78.6K ﹤0.01% 2988
2019
Q3 		$180K Buy
273
+25
+10% +$20.8K ﹤0.01% 2400
2019
Q2 		$192K Sell
248
-185
-43% -$130K ﹤0.01% 2343
2019
Q1 		$306K Sell
433
-20
-4% -$12K ﹤0.01% 1958
2018
Q4 		$211K Sell
453
-32
-7% -$20.6K ﹤0.01% 2054
2018
Q3 		$417K Buy
485
+82
+20% +$59.2K ﹤0.01% 1601
2018
Q2 		$278K Buy
403
+43
+12% +$21.9K ﹤0.01% 1727
2018
Q1 		$161K Buy
360
+171
+90% +$82.9K ﹤0.01% 2149
2017
Q4 		$82K Sell
189
-31
-14% -$14.1K ﹤0.01% 2732
2017
Q3 		$109K Buy
220
+44
+25% +$22K ﹤0.01% 2329
2017
Q2 		$97K Buy
176
+17
+11% +$10.8K ﹤0.01% 2331
2017
Q1 		$105K Buy
159
+88
+124% +$47K ﹤0.01% 2128
2016
Q4 		$24K Buy
71
+70
+7,000% +$22.5K ﹤0.01% 3114
2016
Q3 		$0 Hold
1
– – ﹤0.01% 4633
2016
Q2 		$0 Buy
+1
New +$218 ﹤0.01% 4522

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Advisor Group's TVRD Position: Q4 2019 in Review

Advisor Group reduced its Tvardi Therapeutics (TVRD) stake by 41% in Q4 2019, selling an estimated $78.6K and leaving 161 shares worth $94K. The position accounts for ﹤0.01% of the portfolio, ranked #2988.

Advisor Group first reported a position in TVRD in Q2 2016 and has held it in 15 quarters since. The position peaked at $417K in Q3 2018. 151 funds tracked by Wall St. Rank hold TVRD as of Q4 2019.

  • Advisor Group held 161 shares of Tvardi Therapeutics worth $94K as of Q4 2019.
  • Advisor Group sold 112 Tvardi Therapeutics shares in Q4 2019, an estimated $78.6K.
  • Tvardi Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2988 holding.
  • Advisor Group first reported a position in Tvardi Therapeutics in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Tvardi Therapeutics position peaked at $417K in Q3 2018.
  • 151 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.